Drug induced liver injury – a 2023 update

References

• Adair, K., X. Meng, and D. J. Naisbitt. 2021. Drug hapten‐specific T‐cell activation: Current status and unanswered questions. Proteomics 21 (17–18):e2000267. doi:10.1002/pmic.202000267.
   PubMed Web of Science ®Google Scholar
• Adam, R., V. Karma, V. Cailliez, J. G. O Grady, D. Mirza, D. Cherqui, J. Klempnauer, M. Salizzoni, J. Pratschke, N. Jamieson, et al. 2018. Annual report of the European liver transplant registry (ELTR) - 50-year evolution of liver transplantation. Transpl. Int. 31:1293–317. doi:10.1111/tri.13358.
   PubMed Web of Science ®Google Scholar
• Ahmad, J., and J. Odin. 2017. Epidemiology and genetic risk factors of drug hepatotoxicity. Clin. Liver Dis 21 (1):55–72. doi:10.1016/j.cld.2016.08.004.
   PubMed Web of Science ®Google Scholar
• Allard, J., S. Bucher, J. Massart, P. J. Ferron, D. L. Guillou, R. Loyant, Y. Daniel, Y. Launay, N. Buron, K. Begriche, et al. 2021. Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: Proof of multiple mechanism-based toxicity. Cell Biol. Toxicol. 37 (2):151–75. doi:10.1007/s10565-020-09537-1.
   PubMed Web of Science ®Google Scholar
• Allen, K., H. Jaeschke, and B. L. Copple. 2011. Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. Am. J. Pathol. 178 (1):175–86. doi:10.1016/j.ajpath.2010.11.026.
   PubMed Web of Science ®Google Scholar
• Almazroo, O., M. Miah, and R. Venkataramanan. 2017. Drug metabolism in the liver. Clin. Liver Dis 21 (1):1–20. doi:10.1016/j.cld.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Alqahtani, S. A., J. M. Pail, R. Biswas, T. Arshad, L. Henry, and Z. M. Younossi. 2021. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol. Commun. 5:1833–47. doi:10.1002/hep4.1765.
   PubMed Web of Science ®Google Scholar
• Amadi, C., and O. Orisakwe. 2018. ‘Herb-induced liver injuries in developing nations: An update. Toxics 6 (2):24. doi:10.3390/toxics6020024.
   PubMed Web of Science ®Google Scholar
• Andrade, R. J., G. P. Aithal, E. S. Björnsson, N. Kaplowitz, G. A. Kullak-Ublick, D. Larrey, T. H. Karlsen, and European Association of the Study of the Liver. 2019. EASL clinical practice guidelines: Drug-induced liver injury. J. Hepatol. 70 (6):1222–61. doi:10.1016/j.jhep.2019.02.014.
   PubMed Web of Science ®Google Scholar
• Andrade, R., N. Chalasani, E. Björnsson, A. Suzuki, G. Kullak-Ublick, P. Watkins, H. Devarbhavi, M. Merz, M. Lucena, N. Kaplowitz, et al. 2019. Drug-induced liver injury. Nat. Rev. Dis. Prim. 5:58. doi:10.1038/s41572-019-0105-0.
   PubMed Web of Science ®Google Scholar
• Bechmann, L., P. Manka, J. Best, F. Saner, A. Paul, A. Canbay, and G. Gerken. 2014. Medikamentös-toxische Schädigung als wichtigste Ätiologie des akuten Leberversagens. Dtsch. Med. Wochenschr. 139:878–82. doi:10.1055/s-0034-1369932.
   PubMedGoogle Scholar
• Björnsson, E. S. 2021. Clinical management of patients with drug-induced liver injury (DILI). Ueg. J 9:781–86. doi:10.1002/ueg2.12113.
   PubMed Web of Science ®Google Scholar
• Björnsson, E., O. Bergmann, H. Björnsson, R. Kvaran, and S. Olafsson. 2013. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144 (7):1419. doi:10.1053/j.gastro.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Björnsson, K., and S. Björnsson. 2022. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur. J. Intern. Med. 97:26–31. doi:10.1016/j.ejim.2021.10.035.
   PubMed Web of Science ®Google Scholar
• Björnsson, E., B. Gunnarsson, G. Gröndal, J. Jonasson, R. Einarsdottir, B. Ludviksson, B. Gudbjörnsson, and S. Olafsson. 2015. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin. Gastroenterol. Hepatol. 13 (3):602–08. doi:10.1016/j.cgh.2014.07.062.
   PubMed Web of Science ®Google Scholar
• Bocci, G., T. I. Oprea, and L. Z. Benet. 2022. State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): New additions, revisions, and citation references. Aaps. J 24 (2):37. doi:10.1208/s12248-022-00687-0.
   PubMed Web of Science ®Google Scholar
• Bock, F., and S. Tait. 2020. Mitochondria as multifaceted regulators of cell death. Nat. Rev. Mol. Cell Biol. 21 (2):85–100. doi:10.1038/s41580-019-0173-8.
   PubMed Web of Science ®Google Scholar
• Bonaventura, A., A. Vecchié, T. S. Wang, E. Lee, P. C. Cremer, B. Carey, P. Rajendram, K. M. Hudock, L. Korbee, B. W. Van Tassell, et al. 2020. Targeting GM-CSF in COVID-19 pneumonia: Rationale and strategies. Front. Immunol 11:1625. doi:10.3389/fimmu.2020.01625.
   PubMed Web of Science ®Google Scholar
• Bottcher, J. P., P. A. Knolle, and D. Stabenow. 2011. Mechanisms balancing tolerance and immunity in the liver. Dig. Dis. 29:384–90. doi:10.1159/000329801.
   PubMed Web of Science ®Google Scholar
• British Liver Trust. 2023. Accessed October 4 2023. https://britishlivertrust.org.uk/
   Google Scholar
• Cai, S. Y., and J. L. Boyer. 2021. The role of bile acids in cholestatic liver injury. Ann. Transl. Med. 9:737. doi:10.21037/atm-20-5110.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., H. Bonkovsky, R. Fontana, W. Lee, A. Stolz, J. Talwalkar, K. Reddy, P. Watkins, V. Navarro, H. Barnhart, et al. 2015. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 148:1340–52. doi:10.1053/j.gastro.2015.03.006.
   PubMed Web of Science ®Google Scholar
• Chan, R., and L. Z. Benet. 2017. Evaluation of DILI predictive hypotheses in early drug development. Chem. Res. Toxicol. 30 (4):1017–29. doi:10.1021/acs.chemrestox.7b00025.
   PubMed Web of Science ®Google Scholar
• Cheng, M. L., D. Nakib, C. T. Perciani, and S. A. MacParland. 2021. The immune niche of the liver. Clin. Sci. 135 (20):2445–66. doi:10.1042/CS20190654.
   Web of Science ®Google Scholar
• Chen, M., A. Suzuki, J. Borlak, R. Andrade, and M. Lucena. 2015. Drug-induced liver injury: Interactions between drug properties and host factors. J. Hepatol. 63 (2):503–14. doi:10.1016/j.jhep.2015.04.016.
   PubMed Web of Science ®Google Scholar
• Chen, Q., M. Yu, Z. Tian, Y. Cui, D. Deng, T. Rong, Z. Liu, M. Song, Z. Li, X. Ma, et al. 2022. Exogenous glutathione protects IPEC-J2 cells against oxidative stress through a mitochondrial mechanism. Molecules 27 (8):2416. doi:10.3390/molecules27082416.
   PubMed Web of Science ®Google Scholar
• Christrup, L. 1997. Morphine metabolites. Acta. Anaesthesiol. Scand. 41 (1):116–22. doi:10.1111/j.1399-6576.1997.tb04625.x.
   PubMed Web of Science ®Google Scholar
• Clinton, J., S. Kiparizoska, S. Aggarwal, S. Woo, W. Davis, and J. Lewis. 2021. Drug-induced liver injury: Highlights and controversies in the recent literature. Drug. Safety 44 (11):1125–49. doi:10.1007/s40264-021-01109-4.
   PubMed Web of Science ®Google Scholar
• Daly, A. K., and C. P. Day. 2012. Genetic association studies in drug-induced liver injury. Drug Metab. Rev. 44 (1):116–26. doi:10.3109/03602532.2011.605790.
   PubMed Web of Science ®Google Scholar
• Danan, G., and C. Benichou. 1993. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol 46:1323–30. doi:10.1016/0895-4356(93)90101-6.
   PubMed Web of Science ®Google Scholar
• Danan, G., and R. Teschke. 2016. RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci. 17:14. doi:10.3390/ijms17010014.
   Web of Science ®Google Scholar
• Dara, L., Z. Liu, and N. Kaplowitz. 2016. Questions and controversies: The role of necroptosis in liver disease. Cell. Death Discovery 2 (1):16089. doi:10.1038/cddiscovery.2016.89.
   PubMedGoogle Scholar
• David, S., and J. P. Hamilton. 2010. Drug-induced liver injury. US. Gastroenterol. Hepatol. Rev. 6:73–80.
   PubMedGoogle Scholar
• De Abajo, F., D. Montero, M. Madurga, and L. García-Rodríguez. 2004. Acute and clinically relevant drug-induced liver injury: A population-based case-control study. Br. J. Clin. Pharmacol 58:71–80. doi:10.1111/j.1365-2125.2004.02133.x.
   PubMed Web of Science ®Google Scholar
• De Valle, M., V. Klinteberg, N. Alem, R. Olsson, and E. Björnsson. 2006. Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment. Pharmacol. Ther. 24 (8):1187–95. doi:10.1111/j.1365-2036.2006.03117.x.
   PubMed Web of Science ®Google Scholar
• Devarbhavi, H., G. Aithal, S. Treeprasertsuk, H. Takikawa, Y. Mao, S. M. Shasthry, S. Hamid, S. Tan, C. Philips, J. George, et al. 2021. Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines. Hepatol. Int. 15:258–82. doi:10.1007/s12072-021-10144-3.
   PubMed Web of Science ®Google Scholar
• Doherty, D. G. 2016. Immunity, tolerance and autoimmunity in the liver: A comprehensive review. J. Autoimmun. 66:60–75. doi:10.1016/j.jaut.2015.08.020.
   PubMed Web of Science ®Google Scholar
• Eiswerth, M., M. Heckroth, A. Ismail, D. Gondim, and R. Kaufman. 2022. Infliximab-induced vanishing bile duct syndrome. Cureus 14. doi:10.7759/cureus.21940.
   Google Scholar
• Fernandez-Checa, J. C., P. Bagnaninchi, H. Ye, P. Sancho-Bru, J. M. Falcon-Perez, F. Royo, C. Garcia-Ruiz, O. Konu, J. Miranda, O. Lunov, et al. 2021. Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European drug-induced liver injury Network [PRO-EURO-DILI-NET]. J. Hepatol. 75:935–59. doi:10.1016/j.jhep.2021.06.021.
   PubMed Web of Science ®Google Scholar
• Fisher, K., R. Vuppalanchi, and R. Saxena. 2015. Drug-induced liver injury. Arch. Pathol. Lab. Med. 139 (7):876–87. doi:10.5858/arpa.2014-0214-RA.
   PubMed Web of Science ®Google Scholar
• Fontana, R. J., E. S. Bjornsson, R. Reddy, and P. J. Andrade. 2023. The evolving profile of idiosyncratic drug-induced liver injury. Clin. Gastroenterol. Hepatol. 8:2088–99. doi:10.1016/j.cgh.2022.12.040.
   Google Scholar
• Fyfe, B., F. Zaldana, and C. Liu. 2018. The pathology of acute liver failure. Clin. Liver Dis 22 (2):257–68. doi:10.1016/j.cld.2018.01.003.
   PubMed Web of Science ®Google Scholar
• Galluzzi, L., I. Vitale, S. Aaronson, J. Abrams, D. Adam, P. Agostinis, E. Alnemri, L. Altucci, I. Amelio, D. Andrews, et al. 2018. Molecular mechanisms of cell death: Recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 25:486–541. doi:10.1038/s41418-017-0012-4.
   PubMed Web of Science ®Google Scholar
• Garcia-Cortes, M., M. Robles-Diaz, C. Stephens, A. Ortega-Alonso, I. Lucena, and R. Andrade. 2020. Drug induced liver injury: An update. Arch. Toxicol. 94 (10):3381–407. doi:10.1007/s00204-020-02885-1.
   PubMed Web of Science ®Google Scholar
• Gerussi, A., A. Natalini, F. Antonangeli, C. Mancuso, E. Agostinetto, D. Barisani, F. Di Rosa, R. Andrade, and P. Invernizzi. 2021. Immune-mediated drug-induced liver injury: Immunogenetics and experimental models. Int. J. Mol. Sci. 22 (9):4557. doi:10.3390/ijms22094557.
   PubMed Web of Science ®Google Scholar
• Grewal, P., and J. Ahmad. 2019. Bile duct injury due to drug induced liver injury. Curr. Hepatology. Rep 18:269–73. doi:10.1007/s11901-019-00474-0.
   PubMedGoogle Scholar
• Gupta, A., M. Madhavan, K. Sehgal, N. Nair, S. Mahajan, T. Sehrawat, B. Bikdeli, N. Ahluwalia, J. C. Ausiello, E. Wan, et al. 2020. Extrapulmonary manifestations of COVID-19. Nat. Med. 26:1017–32. doi:10.1038/s41591-020-0968-3.
   PubMed Web of Science ®Google Scholar
• Hamilton, L. A., A. Collins-Yoder, and R. E. Collins. 2016. Drug-induced liver injury. Advan Crit. Care 27 (4):430–40. doi:10.4037/aacnacc2016953.
   PubMedGoogle Scholar
• Hawton, K., H. Bergen, S. Simkin, S. Dodd, P. Pocock, W. Bernal, D. Gunnell, and N. Kapur. 2013. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and wales: Interrupted time series analyses. Br. Med. J 346 (feb07 1):f403. doi:10.1136/bmj.f403.
   PubMedGoogle Scholar
• He, J., D. R. Morales, and B. Gutherie. 2020. Exclusion rates in randomized controlled trials of treatments for physical conditions: A systematic review. Trials 21:228. doi:10.1186/s13063-020-4139-0.
   PubMedGoogle Scholar
• Heymann, F., J. Peusquens, I. Ludwig-Portugall, M. Kohlhepp, C. Ergen, P. Niemietz, C. Martin, N. van Rooijen, J. C. Ochando, G. J. Randolph, et al. 2015. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 62 (1):279–91. doi:10.1002/hep.27793.
   PubMed Web of Science ®Google Scholar
• Hosack, T., D. Damry, and S. Biswas. 2023. Drug-induced liver injury: A comprehensive review. Therap. Adv. Gastroenterol. 16:17562848231163410. doi:10.1177/17562848231163410.
   Web of Science ®Google Scholar
• Hughes, T., N. Flynn, N. Dang, and S. Swamidass. 2021. Modeling the bioactivation and subsequent reactivity of drugs. Chem. Res. Toxicol. 34 (2):584–600. doi:10.1021/acs.chemrestox.0c00417.
   PubMed Web of Science ®Google Scholar
• Hughes, J., S. Rees, S. Kalindjian, and K. Philpott. 2011. Principles of early drug discovery. Br. J. Pharmacol. 162 (6):1239–49. doi:10.1111/j.1476-5381.2010.01127.x.
   PubMed Web of Science ®Google Scholar
• Hui, D. S., E. I Azhar, T. A. Madani, F. Ntoumi, R. Kock, O. Dar, G. Ippolito, T. D. McHugh, Z. A. Memish, C. Drosten, et al. 2020. The continuing 2019-nCov epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 91:264–66. doi:10.1016/j.ijid.2020.01.009.
   PubMed Web of Science ®Google Scholar
• Iorga, A., L. Dara, and N. Kaplowitz. 2017. Drug-induced liver injury: Cascade of events leading to cell death, apoptosis or necrosis. Int. J. Mol. Sci. 18 (5):1018. doi:10.3390/ijms18051018.
   PubMed Web of Science ®Google Scholar
• Isa, S. E., A. O. Ebonyi, N. Y. Shehu, P. Idoko, J. A. Anejo-Okopi, G. Simji, R. U. Odesanya, I. O. Abah, and H. O. Jimoh. 2016. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Int. J. Mycobacteriol 5 (1):21–26. doi:10.1016/j.ijmyco.2015.10.001.
   PubMed Web of Science ®Google Scholar
• Jee, A., S. C. Sernoskie, and J. Uetrecht. 2021. Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges. Int. J. Mol. Sci. 22 (6):2954. doi:10.3390/ijms22062954.
   PubMed Web of Science ®Google Scholar
• Katarey, D., and S. Verma. 2016. Drug-induced liver injury. Clin. Med (Northfield Il) 16:104–09. doi:10.7861/clinmedicine.16-6-s104.
   PubMedGoogle Scholar
• Ke, L., C. Lu, R. Shen, T. Lu, B. Ma, and Y. Hua. 2020. Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010-2019). Front. Pharmacol 11:842. doi:10.3389/fphar.2020.00842.
   PubMed Web of Science ®Google Scholar
• Kermanizadeh, A., N. R. Jacobsen, M. Roursgaard, S. Loft, and P. Møller. 2017. Hepatic hazard assessment of silver nanoparticle exposure in healthy and chronically alcohol fed mice. Toxicol. Sci. 158 (1):176–87. doi:10.1093/toxsci/kfx080.
   PubMed Web of Science ®Google Scholar
• Kermanizadeh, A., J. Valli, K. Sanchez, S. Hutter, A. Pawlowska, G. Whyte, W. Moritz, and V. Stone. 2022. Particulate and drug induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH. Arch. Toxicol. 96:287–303. doi:10.1007/s00204-021-03181-2.
   PubMed Web of Science ®Google Scholar
• Ko, S., J. Russell, L. Molina, and S. Monga. 2020. Liver progenitors and adult cell plasticity in hepatic injury and repair: Knowns and unknowns. Annu. Rev. Pathol 15 (1):23–50. doi:10.1146/annurev-pathmechdis-012419-032824.
   PubMedGoogle Scholar
• Korver, S., J. Bowen, K. Pearson, R. Gonzalez, N. French, K. Park, R. Jenkins, and C. Goldring. 2021. The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Arch. Toxicol. 95 (11):3435–48. doi:10.1007/s00204-021-03121-0.
   PubMed Web of Science ®Google Scholar
• Kozlov, A., J. Lancaster, A. Meszaros, and A. Weidinger. 2017. Mitochondria-mediated pathways of organ failure upon inflammation. Redox. Biol. 13:170–81. doi:10.1016/j.redox.2017.05.017.
   PubMed Web of Science ®Google Scholar
• Krishna, M. 2017. Patterns of necrosis in liver disease. Clin. Liver Dis. 10 (2):53. doi:10.1002/cld.653.
   Google Scholar
• Kubes, P., and C. Jenne. 2018. Immune responses in the liver. Annu. Rev. Immunol. 36 (1):247–77. doi:10.1146/annurev-immunol-051116-052415.
   PubMed Web of Science ®Google Scholar
• Lai, R. T., H. Wang, H. L. Gui, M. Z. Ye, W. J. Dai, X. G. Xiang, G. D. Zhao, W. J. Wang, and Q. Xie. 2012. Clinical and pathological features in 138 cases of drug-induced liver injury. Chin. J. Hepatol 20:185–89. doi:10.3760/cma.j.issn.1007-3418.2012.03.009.
   PubMedGoogle Scholar
• Lammert, C., T. Imler, E. Teal, and N. Chalasani. 2019. Patients with chronic liver disease suggestive of non-alcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin. Gastroenterol. Hepatol. 17:2814–15. doi:10.1016/j.cgh.2018.12.013.
   PubMed Web of Science ®Google Scholar
• Lee, F., and D. A. Lawrence. 2018. From infections to anthropogenic inflicted pathologies: Involvement of immune balance. J. Toxicol. Environ. Health - B. 21:24–46. doi:10.1080/10937404.2017.1412212.
   PubMed Web of Science ®Google Scholar
• Li, X., P. Gao, and J. Niu. 2019. Metabolic comorbidities and risk of development and severity of drug-induced liver injury. Biomed. Res. Int. 18:8764093. doi:10.1155/2019/8764093.
   Google Scholar
• Li, M., Q. Luo, Y. Tao, X. Sun, and C. Liu. 2022. Pharmacotherapies for drug-induced liver injury: A current literature review. Front. Pharmacol 12:806249. doi:10.3389/fphar.2021.806249.
   PubMed Web of Science ®Google Scholar
• Liu, N., J. Liu, B. Zheng, X. Zeng, Z. Ye, X. Huang, W. Liu, Y. Liu, Q. Fang, L. Chen, et al. 2023. Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury. Biomed. Pharmacother. 160:114400. doi:10.1016/j.biopha.2023.114400.
   PubMed Web of Science ®Google Scholar
• LiverTox. 2022. Accessed November 10 2022. https://www.niddk.nih.gov/news/archive/2022/livertox-online-resource-information-drug-induced-liver-injury
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012a. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Abacavir. [Updated 2016 Jan 4]. https://www.ncbi.nlm.nih.gov/books/NBK548225/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012b. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Amoxicillin-Clavulanate. [Updated 2020 Oct 20]. https://www.ncbi.nlm.nih.gov/books/NBK548517/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012c. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Carbamazepine. [Updated 2017 Jan 15]. https://www.ncbi.nlm.nih.gov/books/NBK548097/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012d. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Diclofenac. [Updated 2017b Dec 13]. https://www.ncbi.nlm.nih.gov/books/NBK547953/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012e. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Erythromycin. [Updated 2017 (C) Aug 10]. https://www.ncbi.nlm.nih.gov/books/NBK547881/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012f. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Ibuprofen. [Updated 2018 Apr 16]. https://www.ncbi.nlm.nih.gov/books/NBK547845/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012g. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Sulindac. [Updated 2020 (B) Mar 20]. https://www.ncbi.nlm.nih.gov/books/NBK548315/
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012h. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Rifampin. [Updated 2018 Jun 10].
   Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2012i. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Valproate. [Updated 2020 (C) Jul 31]. https://www.ncbi.nlm.nih.gov/books/NBK548284/
   Google Scholar
• Li, X., W. Wang, S. Yan, W. Zhao, H. Xiong, C. Bao, J. Chen, Y. Yue, Y. Su, and C. Zhang. 2022. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. Front. Pharmacol 13:1019487. doi:10.3389/fphar.2022.1019487.
   PubMed Web of Science ®Google Scholar
• Lorincz, T., K. Jemnitz, T. Kardon, J. Mandl, and A. Szarka. 2015. Ferroptosis is involved in acetaminophen induced cell death. Pathol. Oncol. Res. 21:1115–21. doi:10.1007/s12253-015-9946-3.
   PubMed Web of Science ®Google Scholar
• Low, E., Q. Zheng, E. Chan, and S. Lim. 2020. Drug induced liver injury: East versus West - a systematic review and meta-analysis. Clin. Mol. Hepatol 26:142–54. doi:10.3350/cmh.2019.1003.
   PubMed Web of Science ®Google Scholar
• Lu, S. 2009. Regulation of glutathione synthesis. Mol. Aspects Med. 30 (1–2):42–59. doi:10.1016/j.mam.2008.05.005.
   PubMed Web of Science ®Google Scholar
• Luan, J., and D. Ju. 2018. Inflammasome: A double-edged sword in liver diseases. Front. Immunol. 9:2201. doi:10.3389/fimmu.2018.02201.
   PubMed Web of Science ®Google Scholar
• Lucena, M. I., R. J. Andrade, N. Kaplowitz, M. García-Cortes, M. C. Fernández, M. Romero-Gomez, M. Bruguera, H. Hallal, M. Robles-Diaz, J. F. Rodriguez-González, et al. 2009. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology 49 (6):2001–09. doi:10.1002/hep.22895.
   PubMed Web of Science ®Google Scholar
• Lu, H., C. W. Stratton, and Y. W. Tang. 2020. Outbreak of pneumonia of unknown aetiology in Wuhan, China: The mystery and the miracle. J. Med. Virol. 92:401–02. doi:10.1002/jmv.25678.
   PubMed Web of Science ®Google Scholar
• Marjot, T., G. J. Webb, A. S. Barritt, A. M. Moon, Z. Stamataki, V. W. Wong, and E. Barnes. 2021. COVID-19 and liver disease: Mechanistic and clinical perspectives. Nat. Rev. Gastro. Hepat. 18 (5):348–64. doi:10.1038/s41575-021-00426-4.
   PubMed Web of Science ®Google Scholar
• McGill, M., and H. Jaeschke. 2018. Biomarkers of drug-induced liver injury: Progress and utility in research, medicine, and regulation. Exp. Rev. Molecular Diag. 18:797–807. doi:10.1080/14737159.2018.1508998.
   PubMed Web of Science ®Google Scholar
• McGill, M., and H. Jaeschke. 2019. Biomarkers of drug-induced liver injury. Advan. Pharmacol. 85:221–39.
   PubMedGoogle Scholar
• McGrowder, D. A., F. Miller, M. Anderson Cross, L. Anderson-Jackson, S. Bryan, and L. Dilworth. 2021. Abnormal liver biochemistry tests and acute liver injury in COVID-19 patients: Current evidence and potential pathogenesis. Diseases 9 (3):50. doi:10.3390/diseases9030050.
   PubMedGoogle Scholar
• McPherson, S., M. J. Armstrong, J. F. Cobbold, L. Corless, Q. M. Anstee, R. J. Aspinall, S. T. Barclay, P. N. Brennan, T. M. Cacciottolo, R. D. Goldin, et al. 2022. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): Consensus recommendations from the British association for the study of the liver and British society of gastroenterology NAFLD special interest group. Lancet Gastroenterol. Hepatol. 7:755–69. doi:10.1016/S2468-1253(22)00061-9.
   PubMed Web of Science ®Google Scholar
• Michalopoulos, G. K. 2013. Principles of liver regeneration and growth homeostasis. Compr. Physiol. 3:485–513.
   PubMed Web of Science ®Google Scholar
• Molina, D. K., and V. J. M. DiMaio. 2012. Normal organ weights in men: Part II-the brain, lungs, liver, spleen, and kidneys. Am. J. Forensic Med. Pathol. 33 (4):368–72. doi:10.1097/PAF.0b013e31823d29ad.
   PubMed Web of Science ®Google Scholar
• Muhović, D., J. Bojović, A. Bulatović, B. Vukčević, M. Ratković, R. Lazović, and B. Smolović. 2020. First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19. Liver Int. 40 (8):1901–05. doi:10.1111/liv.14516.
   PubMed Web of Science ®Google Scholar
• Muscate, F., A. Woestemeier, and N. Gagliani. 2021. Functional heterogeneity of CD4+ T cells in liver inflammation. Semin. Immunopathol 43 (4):549–61. doi:10.1007/s00281-021-00881-w.
   PubMed Web of Science ®Google Scholar
• Naseralallah, L. M., B. A. Aboujabal, N. M. Geryo, A. Al Boinin, F. Al Hattab, R. Akbar, W. Umer, L. Abdul Jabbar, M. I. Danjuma, and E. Yunihastuti. 2022. The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome. PLoS One 17 (9):e0268705. doi:10.1371/journal.pone.0268705.
   PubMed Web of Science ®Google Scholar
• NHS. 2023. Accessed November 1 2023. https://www.nhs.uk/
   Google Scholar
• Nicoletti, P., G. P. Aithal, E. S. Bjornsson, R. J. Andrade, A. Sawle, M. Arrese, H. X. Barnhart, E. Bondon-Guitton, P. H. Hayashi, F. Bessone, et al. 2017. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology 152 (5):1078–89. doi:10.1053/j.gastro.2016.12.016.
   PubMed Web of Science ®Google Scholar
• Nicoletti, P., A. Werk, A. Sawle, Y. Shen, T. Urban, S. Coulthard, E. Bjornsson, I. Cascorbi, A. Floratos, T. Stammschulte, et al. 2016. International drug-induced liver injury consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet. Genomics 26:218–24. doi:10.1097/FPC.0000000000000209.
   PubMed Web of Science ®Google Scholar
• Ortega-Alonso, A., C. Stephens, M. Lucena, and R. Andrade. 2016. Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci 17 (5):714. doi:10.3390/ijms17050714.
   PubMed Web of Science ®Google Scholar
• Ostapowicz, G., R. J. Fontana, F. V. Schiødt, A. Larson, T. J. Davern, S. H. Han, T. M. McCashland, A. O. Shakil, J. E. Hay, L. Hynan, et al. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137:947–54. doi:10.7326/0003-4819-137-12-200212170-00007.
   PubMed Web of Science ®Google Scholar
• Ou, P., Y. Chen, B. Li, M. Zhang, X. Liu, F. Li, Y. Li, C. Chen, Y. Mao, and J. Chen. 2015. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. SpringerPlus 4 (1):802. doi:10.1186/s40064-015-1600-8.
   PubMedGoogle Scholar
• Perwitasari, D. A., E. Darmawan, U. A. Mulyani, P. V. Vlies, J. C. Alffenaar, J. Atthobar, and B. Wilffert. 2018. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. Int. J. Mycobacteriol 7:380–86. doi:10.4103/ijmy.ijmy_143_18.
   PubMed Web of Science ®Google Scholar
• Pichler, W. J. 2013. Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatol. Sin. 31 (4):181–90. doi:10.1016/j.dsi.2013.09.005.
   Web of Science ®Google Scholar
• Pollock, N. R., S. McGray, D. J. Colby, F. Noubary, H. Nguyen, T. A. Nguyen, S. Khormaee, S. Jain, K. Hawkins, S. Kumar, et al. 2013. Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test. PLoS One 8 (9):e75616. doi:10.1371/journal.pone.0075616.
   PubMed Web of Science ®Google Scholar
• Popper, H., and F. Schaffner. 1965. The problem of chronicity in liver disease. Progr. Liver Dis. 2:519–38.
   Google Scholar
• Pu, S., Y. Pan, Q. Zhang, T. You, T. Yue, Y. Zhang, and M. Wang. 2023. Endoplasmic reticulum stress and mitochondrial stress in drug-induced liver injury. Molecules 28 (7):3160. doi:10.3390/molecules28073160.
   PubMed Web of Science ®Google Scholar
• Rathi, C., N. Pipaliya, R. Patel, M. Ingle, A. Phadke, and P. Sawant. 2017. Drug induced liver injury at a tertiary hospital in India: Etiology, clinical features and predictors of mortality. Ann. Hepatol 16 (3):442–50. doi:10.5604/01.3001.0009.8600.
   PubMed Web of Science ®Google Scholar
• Real, M., M. S. Barnhill, C. Higley, J. Rosenberg, and J. H. Lewis. 2019. Drug-induced liver injury: Highlights of the recent literature. Drug. Safety 42 (3):365–87. doi:10.1007/s40264-018-0743-2.
   PubMed Web of Science ®Google Scholar
• Reuben, A., D. Koch, W. Lee, and Acute Liver Failure Study Group. 2010. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatology 52:2065–76. doi:10.1002/hep.23937.
   PubMed Web of Science ®Google Scholar
• Riebensahm, C., K. D, A. Sow, N. Semmo, and G. Wandeler. 2019. A closer look at the spectrum of drug-induced liver injury in sub-saharan Africa. Expert. Rev. Clin. Pharmacol 12:875–83. doi:10.1080/17512433.2019.1638251.
   PubMed Web of Science ®Google Scholar
• Robles-Diaz, M., L. Nezic, V. Vujic-Aleksic, and E. Björnsson. 2021. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review. Front. Pharmacol 12:744488. doi:10.3389/fphar.2021.744488.
   PubMed Web of Science ®Google Scholar
• Russmann, S., G. Kullak-Ublick, and I. Grattagliano. 2009. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 16 (23):3041–53. doi:10.2174/092986709788803097.
   PubMed Web of Science ®Google Scholar
• Saha, L., S. Vij, and K. Rawat. 2022. Liver injury induced by COVID-19 treatment - what do we know? World. J. Gastroenterol. 28:6314–27. doi:10.3748/wjg.v28.i45.6314.
   PubMed Web of Science ®Google Scholar
• Saini, R. K., N. Saini, S. Ram, S. L. Soni, V. Suri, P. Malhotra, J. Kaur, I. Verma, S. Sharma, and D. Zohmangaihi. 2020. COVID-19 associated variations in liver function parameters: A retrospective study. Postgrad. Med. J. 98:91–97. doi:10.1136/postgradmedj-2020-138930.
   PubMed Web of Science ®Google Scholar
• Sancho-Bru, P., J. Altamirano, D. Rodrigo-Torres, M. Coll, C. Millan, J. J. Lozano, R. Miquel, V. Arroyo, J. Caballeria, P. Gines, et al. 2012. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 55 (6):1931–41. doi:10.1002/hep.25614.
   PubMed Web of Science ®Google Scholar
• Schutz, C., Z. Ismail, C. J. Proxenos, S. Marais, R. Burton, C. Kenyon, G. Maartens, R. J. Wilkinson, and G. Meintjes. 2012. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S. Afr. Med. J. 102:506–11. doi:10.7196/SAMJ.5650.
   PubMed Web of Science ®Google Scholar
• Segovia-Zafra, A., D. Zeo-Sánchez DE, C. López-Gómez, Z. Pérez-Valdés, E. García-Fuentes, R. J. Andrade, M. I. Lucena, and M. Villanueva-Paz. 2021. Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta. Pharm. Sin B. 11:3685–726. doi:10.1016/j.apsb.2021.11.013.
   PubMed Web of Science ®Google Scholar
• Sgro, C., F. Clinard, K. Ouazir, H. Chanay, C. Allard, C. Guilleminet, C. Lenoir, A. Lemoine, and P. Hillon. 2002. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 36 (2):451–55. doi:10.1053/jhep.2002.34857.
   PubMed Web of Science ®Google Scholar
• Shi, C., B. Hao, Y. Yang, I. Muhammad, Y. Zhang, Y. Chang, Y. Li, C. Li, R. Li, and F. Liu. 2019. JNK signalling pathway mediates acetaminophen-induced hepatotoxicity accompanied by changes of glutathione S-transferase A1 content and expression. Front. Pharmacol 10:1092. doi:10.3389/fphar.2019.01092.
   PubMed Web of Science ®Google Scholar
• Shojaie, L., A. Iorga, and L. Dara. 2020. Cell death in liver diseases: A review. Int. J. Mol. Sci. 21 (24):9682. doi:10.3390/ijms21249682.
   PubMed Web of Science ®Google Scholar
• Stine, J. G., and J. H. Lewis. 2016. Current and future directions in the treatment and prevention of drug-induced liver injury: A systematic review. Expert. Rev. Gastroenterol. Hepatol. 10 (4):517–36. doi:10.1586/17474124.2016.1127756.
   PubMed Web of Science ®Google Scholar
• Suk, K. T., D. J. Kim, C. H. Kim, S. H. Park, J. H. Yoon, Y. S. Kim, G. H. Baik, J. B. Kim, Y. O. Kweon, B. I. Kim, et al. 2012. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 107:1380–87. doi:10.1038/ajg.2012.138.
   PubMed Web of Science ®Google Scholar
• Szabo, G., and J. Petrasek. 2015. Inflammasome activation and function in liver disease. Nat. Rev. Gastroenterol. Hepatol. 12 (7):387–400. doi:10.1038/nrgastro.2015.94.
   PubMed Web of Science ®Google Scholar
• Tasnim, F., X. Huang, C. Lee, F. Ginhoux, and H. Yu. 2021. Recent advances in models of immune-mediated drug-induced liver injury. Front. Toxicol. 3:605392. doi:10.3389/ftox.2021.605392.
   PubMedGoogle Scholar
• Teigs, G., and A. W. Lohse. 2009. Immune tolerance: What is unique about the liver. J. Autoimmun. 34:1–6. doi:10.1016/j.jaut.2009.08.008.
   PubMed Web of Science ®Google Scholar
• Teschke, R., and G. Danan. 2020. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: A comprehensive analysis. Medicines 7:62. doi:10.3390/medicines7100062.
   Google Scholar
• Teschke, R., and G. Danan. 2021a. Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: Highlights and controversies. Int. J. Mol. Sci. 22 (7):3441. doi:10.3390/ijms22073441.
   PubMed Web of Science ®Google Scholar
• Teschke, R., and G. Danan. 2021b. The LiverTox paradox-gaps between promised data and reality check. Diagnostics 11 (10):1754. doi:10.3390/diagnostics11101754.
   Web of Science ®Google Scholar
• Trefts, E., M. Gannon, and D. Wasserman. 2017. The liver. Curr. Biol. 27:1147–51. doi:10.1016/j.cub.2017.09.019.
   PubMed Web of Science ®Google Scholar
• Turpeinen, M., C. Ghiciuc, M. Opritoui, L. Tursas, O. Pelkonen, and M. Pasanen. 2007. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica 37 (12):1367–77. doi:10.1080/00498250701658312.
   PubMed Web of Science ®Google Scholar
• Vargas, J. I., J. P. Arab, F. Bessone, M. I. Lucena, R. J. Andrade, and M. Arrese. 2017. Hepatotoxicity in patients with metabolic syndrome: Causes and consequences. Curr. Hepatology. Rep. 16:286–92. doi:10.1007/s11901-017-0380-8.
   Google Scholar
• Vega, M., M. Verma, D. Beswick, S. Bey, J. Hossack, N. Merriman, A. Shah, V. Navarro, and Drug Induced Liver Injury Network (DILIN). 2017. The incidence of drug - and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug. Safety 40 (9):783–87. doi:10.1007/s40264-017-0547-9.
   PubMed Web of Science ®Google Scholar
• Villanueva-Paz, M., L. Morán, N. López-Alcántara, C. Freixo, R. Andrade, M. Lucena, and F. Cubero. 2021. Oxidative stress in drug-induced liver injury (DILI): From mechanisms to biomarkers for use in clinical practice. Antioxidants 10 (3):390. doi:10.3390/antiox10030390.
   Web of Science ®Google Scholar
• Visentin, M., D. Lenggenhager, Z. Gai, and G. A. Kullak-Ublick. 2018. Drug-induced bile duct injury. BBA- Molecular. Basis Dis. 1864:1498–506. doi:10.1016/j.bbadis.2017.08.033.
   PubMed Web of Science ®Google Scholar
• Vitiello, A., R. La Porta, V. D’Aiuto, and F. Ferrara. 2021. The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver. J 11:11. doi:10.1186/s43066-021-00082-y.
   PubMedGoogle Scholar
• Vuppalanchi, R., R. Gotur, K. R. Reddy, R. J. Fontana, M. Ghabril, A. S. Kosinski, J. Gu, J. Serrano, and N. Chalasani. 2014. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin. Gastroenterol. Hepatol: Off Clin Prac J. Amer Gastroenterol. Ass. 12 (9):1550–55. doi:10.1016/j.cgh.2013.12.016.
   PubMed Web of Science ®Google Scholar
• Wang, Q., A. Huang, J. B. Wang, and Z. Zou. 2021. Chronic drug-induced liver injury: Updates and future challenges. Front. Pharmacol 12:627133. doi:10.3389/fphar.2021.627133.
   PubMed Web of Science ®Google Scholar
• Woolbright, B. L., and H. Jaeschke. 2018. Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity. Curr. Pharmacol. Rep. 4:346–57. doi:10.1007/s40495-018-0147-0.
   PubMedGoogle Scholar
• World Federation of Societies of Anaesthesiologists. 2023. The role of the liver in drug metabolism anaesthesia. Accessed March 2 2023. https://resources.wfsahq.org/wp-content/uploads/179_english-1.pdf
   Google Scholar
• Xiang, D. D., J. T. Liu, Z. B. Zhong, Y. Xiong, H. Y. Kong, H. J. Yu, T. Peng, and J. Q. Hunag. 2023. MicroRNA-29a-3p prevents drug-induced acute liver failure through inflammation-related pyroptosis inhibition. Cur. Med. Sci. 43:456–68. doi:10.1007/s11596-023-2734-5.
   PubMed Web of Science ®Google Scholar
• Xie, H., J. Zhao, N. Lian, S. Lin, Q. Xie, and H. Zhuo. 2020. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int. 40 (6):1321–26. doi:10.1111/liv.14449.
   PubMed Web of Science ®Google Scholar
• Xu, H. M., Y. Chen, J. Xu, and Q. Zhou. 2012. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J. Gastroenterol. 18:5972–78. doi:10.3748/wjg.v18.i41.5972.
   PubMed Web of Science ®Google Scholar
• Yan, M., Y. Huo, S. Yin, and H. Hu. 2018. Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions. Redox. Biol. 17:27–283. doi:10.1016/j.redox.2018.04.019.
   Web of Science ®Google Scholar
• Yokoi, T., and S. Oda. 2021. Models of idiosyncratic drug-induced liver injury. Annu. Rev. Pharmacol. Toxicol. 61 (1):247–68. doi:10.1146/annurev-pharmtox-030220-015007.
   PubMedGoogle Scholar
• Yu, Y. C., Y. M. Mao, C. W. Chen, J. J. Chen, J. Chen, W. M. Cong, Y. Ding, Z. P. Duan, Q. C. Fu, X. Y. Guo, et al. 2017. Drug-induced liver injury (DILI) study group, Chinese Society of Hepatology (CSH), Chinese medical association. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol. Int. 11:221–41. doi:10.1007/s12072-017-9793-2.
   PubMed Web of Science ®Google Scholar
• Zeke, A., M. Misheva, A. Reményi, and M. Bogoyevitch. 2016. JNK signaling: Regulation and functions based on complex protein-protein partnerships. Microbiol. Mol. Biol. R. 80 (3):793–835. doi:10.1128/MMBR.00043-14.
   PubMed Web of Science ®Google Scholar
• Zhai, G., M. Li, Y. Wang, and J. Wu. 2021. Drug-induced liver disturbance during the treatment of COVID-19. Front. Pharmacol. 12:719308. doi:10.3389/fphar.2021.719308.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., S. Li, Z. Zhang, K. Yu, X. Duan, L. Long, S. Zhang, M. Jiang, and O. Liu. 2020. Clinical features, risk factors, and prognostic markers of drug-induced liver injury in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. Indian J. Dermatol. 65 (4):274–78. doi:10.4103/ijd.IJD_217_19.
   PubMed Web of Science ®Google Scholar
• Zhao, S., J. Jiang, Y. Jing, W. Liu, X. Yang, X. Hou, L. Gao, and L. Wei. 2020. The concentration of tumour necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity. Cell. Death Dis. 11:1–13. doi:10.1038/s41419-020-2264-z.
   PubMed Web of Science ®Google Scholar
• Zhao, M., M. Jingsong, M. Li, Y. Zhang, B. Jiang, X. Zhao, C. Huai, L. Shen, N. Zhang, L. He, et al. 2021. Cytochrome P450 enzymes and drug metabolism in humans. Int. J. Mol. Sci 22:1280. doi:10.3390/ijms222312808.
   PubMed Web of Science ®Google Scholar
• Zhao, S. W., Y. M. Li, Y. L. Li, and C. Su. 2023. Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. World. J. Gastroenterol 29:241–56. doi:10.3748/wjg.v29.i2.241.
   PubMed Web of Science ®Google Scholar